论文部分内容阅读
目的观察脑血疏口服液对出血性中风的治疗作用。方法连续收集急性高血压性脑出血且证属气虚血瘀患者30例,并按1∶1匹配对照组患者,比较血肿吸收情况,中风病病类诊断评分,神经功能缺损评分(NIHSS)及3个月改良Rankin评分,评价脑血疏口服液对出血性中风的治疗作用。结果两组患者基线资料无明显差异,脑血疏口服液组血肿吸收良好,中风病病类诊断评分及NIHSS评分的改变无统计学意义,3个月预后良好(mRS 0-2分)的患者比例同对照组比较无统计学意义。结论脑血疏口服液可促进颅内血肿的吸收,但不能改善出血性中风3个月临床预后,可能与研究样本较小有关,有必要扩大样本数进一步研究。
Objective To observe the therapeutic effect of Naoxuesu Oral Liquid on hemorrhagic stroke. Methods Thirty consecutive cases of acute hypertensive intracerebral hemorrhage and evidence of deficiency of Qi and blood stasis were collected. Patients in the control group were matched according to the ratio of 1: 1, the absorption of hematoma, the diagnostic score of stroke disease, NIHSS and 3 Month improved Rankin score, evaluation of cerebral blood sparse oral liquid on the treatment of hemorrhagic stroke. Results There was no significant difference in baseline data between the two groups. The hematoma absorption of Naoxuesu oral liquid group was good, the diagnostic score of stroke disease and NIHSS score had no significant change, and the patients with good prognosis of 3 months (mRS 0-2) Ratio with the control group was not statistically significant. Conclusion Naoxuesu Oral Liquid can promote the absorption of intracranial hematoma, but it can not improve the clinical prognosis of hemorrhagic stroke for 3 months, which may be related to the smaller sample size. It is necessary to expand the sample size for further study.